Joseph Payne, Arcturus CEO (Arcturus via YouTube)
November 2, 2022 09:12 AM EDTUpdated 09:34 AM
Deals

CSL stacks up $4.5B in chips — with a $200M ante — to wa­ger on the next-gen mR­NA wave

John Carroll

Editor & Founder

Aus­tralian phar­ma gi­ant CSL is mak­ing a late bid for mR­NA glo­ry, and they’ve lined up one of the al­so-ran US Covid-19 biotechs tout­ing their …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

As the XBI suf­fers, Q1 shows a few com­fort­ing signs of un­der­ly­ing sta­bil­i­ty

Makary, in one of first com­ments on FDA pol­i­cy, floats new path­way for rare dis­ease drugs

Roche promis­es $50B in­vest­ment in the US as phar­ma tar­iffs inch clos­er

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

FDA plans to ban phar­ma em­ploy­ees from serv­ing on ad­comms. The im­pact will be lim­it­ed

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times